Page 63 - Read Online

Page 16 of 20 Jiang et al. Microbiome Res Rep 2024;3:47 https://dx.doi.org/10.20517/mrr.2024.12

Amuc_2172 and Amuc_2109 could be potential drugs for colitis and inspire novel strategies in the
treatment of intestinal-related diseases.

DECLARATIONS
Authors’ contributions
Performed the literature search and drafted the manuscript: Jiang P, Ji S
Contributed intellectually and provided critical comments on the manuscript: Zhang M, Su D, Jiang P,
Goncalves VBE, Ji S
Supervised the drafting and revised the manuscript: Zhang M, Zhao Y, Xu G
All authors read and approved the final version of the manuscript for publication.

Availability of data and materials
All data relevant to the review are included in the article.

Financial support and sponsorship
This work was supported by grants from the Natural Science Foundation of China (No. 82322010,
82273272, 81970487) and the Shanghai Pujiang Program (No. 21PJ1409500).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial
microorganisms. Nat Rev Gastroenterol Hepatol 2022;19:625-37. DOI PubMed
2. Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol 2017;8:1765.
DOI PubMed PMC
3. Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. The mucin degrader Akkermansia muciniphila is an abundant
resident of the human intestinal tract. Appl Environ Microbiol 2008;74:1646-8. DOI PubMed PMC
4. Jiang Y, Xu Y, Zheng C, et al. Acetyltransferase from Akkermansia muciniphila blunts colorectal tumourigenesis by reprogramming
tumour microenvironment. Gut 2023;72:1308-18. DOI PubMed
5. Hansen CHF, Krych L, Nielsen DS, et al. Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces
diabetes incidence in the NOD mouse. Diabetologia 2012;55:2285-94. DOI PubMed
6. Keshavarz Azizi Raftar S, Ashrafian F, Yadegar A, et al. The protective effects of live and pasteurized Akkermansia muciniphila and
its extracellular vesicles against HFD/CCl4-induced liver injury. Microbiol Spectr 2021;9:e0048421. DOI PubMed PMC
7. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading
bacterium. Int J Syst Evol Microbiol 2004;54:1469-76. DOI PubMed
8. Dubourg G, Cornu F, Edouard S, Battaini A, Tsimaratos M, Raoult D. First isolation of Akkermansia muciniphila in a blood-culture
sample. Clin Microbiol Infect 2017;23:682-3. DOI PubMed
9. Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading
member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol 2007;73:7767-70. DOI
PubMed PMC
10. Png CW, Lindén SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization
of mucin by other bacteria. Am J Gastroenterol 2010;105:2420-8. DOI PubMed